Article Text

Download PDFPDF

7 Update on the artificial pancreas Hybrid closed loop: a 10-day initiation protocol of advanced hybrid closed loop system in children and adolescents with type 1 diabetes, previously treated with multiple daily injections
  1. Goran Petrovski
  1. Department of Pediatric Medicine, Division of Endocrinology and Diabetes, Sidra Medicine, Education City North Campus, Doha, Qatar


Introduction Advanced Hybrid Closed Loop (AHCL) systems provide superior glycemic control in children and adolescents with Type 1 Diabetes (T1D). Current studies included participants with previous pump and Continuous Glucose Monitoring (CGM) experience.

Objectives We aimed to study transitioning these patients on Multiple Daily Injections (MDI) without prior pump experience to AHCL systems within a short period, utilizing a structured initiation protocol and the glycemic control they achieved with the MiniMed 780G system.

Methods Children and adolescents (aged 7–17 years) with T1D on MDI therapy and HbA1c below 12.5% were recruited in this prospective open label single-arm, single-center study. All participants followed a structured initiation protocol including 4 steps: step 1: AHCL system assessment (1 hour discussion with educator); step 2: AHCL system training (2-hours sessions in 4 consecutive days with groups of 2 to 3 participants and caregivers); step 3: SAP use for 3 days; step 4: AHCL system use for 12 weeks, cumulating in 10 days from MDI to AHCL initiation. The primary outcome of the study was the change in the time spent in the target in range (TIR) of 70–180 mg/dl and HbA1c from baseline (MDI + CGM, 1 week) to study phase (AHCL, 12 weeks).

Results 34 participants were recruited and all of them completed the 12 weeks study. TIR increased from 42.1±18.7% at baseline to 78.8 ±6.1% in the study phase (p<0.001). HbA1c decreased from 8.6±1.7% (70±18.6 mmol/mol) at baseline, to 6.5±0.7% (48±7.7 mmol/mol) at the end of the study (p=0.001). The participants used the sensor for a median of 96% of the time and spent a median of 90% in AHCL during the 12 weeks. No episodes of severe hypoglycemia or DKA were reported.

Conclusions Children and adolescents with T1D on MDI therapy who initiated the AHCL system following a 10-days structured protocol achieved the internationally recommended goals of glycemic control with TIR >70% and a HbA1c of <7%.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.